The FDA’s Office of Generic Drugs on July 2, 2026, issued a public roster of all abbreviated new drug applications (ANDAs) granted Competitive Generic Therapy (CGT) designation under section 506H of the Federal Food, Drug, and Cosmetic Act. Updated every two weeks, the compilation details each approved CGT product’s reference listed drug, ANDA number, applicant, active ingredient, dosage form and strength, approval date, eligibility for 180‑day CGT exclusivity, any forfeiture status, and the date of first commercial marketing. According to the agency, a CGT designation itself does not ensure exclusivity; eligibility still depends on whether unexpired patents or exclusivities are in place at the time of submission. Outcomes appear as “Yes,” “No,” “Deferred,” “Relinquished,” or “N/A.”
This new table delivers what market observers had long anticipated: a current, centralized view of which generics have secured, or forfeited, CGT exclusivity. That transparency can help payers, buyers, and investors assess how quickly competition enters small or specialized markets. It also allows regular tracking of forfeitures, a major signal for pricing movements. Under statute, a first CGT filer that does not launch within 75 days of approval gives up that 180‑day exclusivity. Now the agency’s updates make such lapses visible in real time.
The practical effect may be tighter accountability among smaller generic sponsors. Publicly posted forfeiture data could highlight launch delays related to manufacturing or contracting setbacks. Deferred exclusivity decisions, meanwhile, point to cases where patent or exclusivity issues remain unsettled. For buyers and PBMs, the list functions as an early read on when genuine multisource competition might reach products once limited to a single, high‑priced supplier. Analysts will likely be watching whether a growing number of CGT designations starts to correspond with quicker price compression in historically thin markets. For broader coverage of generic pricing trends, see RxInfo.ai.
